Rigel Q2 product sales up 14%; net income falls to $17.3 million; guidance raised
Rigel reported second quarter 2026 total revenues of $78.7 million, down from $101.7 million a year earlier, which included $40.0 million in non-cash collaboration revenue. Net income was $17.3 million, or $0.88 per diluted share, versus $59.6 million, or $3.28 per diluted share, in the prior year period. The company raised its 2026 total revenue outlook to $285 million to $295 million, excluding VEPPANU, which it in-licensed in June and expects to launch in mid-August.
Key points
- Net product sales rose 14% to $67.0 million; TAVALISSE $47.4 million (up 18%), REZLIDHIA $8.9 million (up 27%), GAVRETO $10.7 million (down 10%).
- Total revenues were $78.7 million versus $101.7 million; the prior year included $40.0 million in non-cash revenue tied to Eli Lilly.
- 2026 total revenue guidance raised to $285 million to $295 million from $275 million to $290 million.
- Rigel paid a $70.0 million upfront payment for VEPPANU; cash and short-term investments were $95.3 million at June 30, 2026, versus $155.0 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.